Akari Therapeutics, Plc
AKTX
$0.925
-$0.0249-2.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.61% | -20.43% | -5.71% | -18.10% | -15.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.17% | -16.34% | 5.27% | 4.26% | -9.87% |
| Operating Income | 33.17% | 16.34% | -5.27% | -4.26% | 9.87% |
| Income Before Tax | 39.07% | -8.17% | -97.75% | -116.37% | -103.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.07% | -8.17% | -97.75% | -116.37% | -103.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.07% | -8.17% | -97.75% | -116.37% | -103.56% |
| EBIT | 33.17% | 16.34% | -5.27% | -4.26% | 9.87% |
| EBITDA | 33.16% | 16.29% | -5.21% | -4.21% | 9.92% |
| EPS Basic | 80.00% | 56.18% | -1.50% | -33.82% | -23.63% |
| Normalized Basic EPS | 82.00% | 66.99% | 15.23% | -20.05% | -15.71% |
| EPS Diluted | 80.00% | 56.18% | -1.32% | -33.60% | -23.46% |
| Normalized Diluted EPS | 82.00% | 66.99% | 15.37% | -19.85% | -15.55% |
| Average Basic Shares Outstanding | 252.97% | 221.60% | 161.59% | 89.53% | 63.77% |
| Average Diluted Shares Outstanding | 257.14% | 226.92% | 166.29% | 89.41% | 63.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |